Cargando…

Changes in parents' psychotropic medication use following child's cancer diagnosis: A fixed‐effects register‐study in Finland

BACKGROUND: Symptoms of depression and anxiety are elevated among parents of children with cancer. However, knowledge of parents' psychotropic medication use following child's cancer diagnosis is scarce. METHODS: We use longitudinal Finnish register data on 3266 mothers and 2687 fathers wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Metsä‐Simola, Niina S., Remes, Hanna M., Hiltunen, Elina M., Martikainen, Pekka T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9385598/
https://www.ncbi.nlm.nih.gov/pubmed/35345057
http://dx.doi.org/10.1002/cam4.4662
_version_ 1784769623067983872
author Metsä‐Simola, Niina S.
Remes, Hanna M.
Hiltunen, Elina M.
Martikainen, Pekka T.
author_facet Metsä‐Simola, Niina S.
Remes, Hanna M.
Hiltunen, Elina M.
Martikainen, Pekka T.
author_sort Metsä‐Simola, Niina S.
collection PubMed
description BACKGROUND: Symptoms of depression and anxiety are elevated among parents of children with cancer. However, knowledge of parents' psychotropic medication use following child's cancer diagnosis is scarce. METHODS: We use longitudinal Finnish register data on 3266 mothers and 2687 fathers whose child (aged 0–19) was diagnosed with cancer during 2000–2016. We record mothers' and fathers' psychotropic medication use (at least one annual purchase of anxiolytics, hypnotics, sedatives, or antidepressants) 5 years before and after the child's diagnosis and assess within‐individual changes in medication use by time since diagnosis, cancer type, child's age, presence of siblings, and parent's living arrangements and education using linear probability models with the individual fixed‐effects estimator. The fixed‐effects models compare each parent's annual probability of psychotropic medication use after diagnosis to their annual probability of medication use during the 5‐year period before the diagnosis. RESULTS: Psychotropic medication use was more common among mothers than fathers already before the child's diagnosis, 11.2% versus 7.3%. Immediately after diagnosis, psychotropic medication use increased by 6.0 (95% CI 4.8–7.2) percentage points among mothers and by 3.2 (CI 2.1–4.2) percentage points among fathers. Among fathers, medication use returned to pre‐diagnosis level by the second year, except among those whose child was diagnosed with acute lymphoblastic leukemia or lymphoblastic lymphoma. Among mothers of children with a central nervous system cancer, medication use remained persistently elevated during the 5‐year follow‐up. For mothers with other under‐aged children or whose diagnosed child was younger than 10 years, the return to pre‐diagnosis level was also slow. CONCLUSIONS: Having a child with cancer clearly increases parents' psychotropic medication use. The increase is smaller and more short‐lived among fathers, but among mothers its duration depends on both cancer type and family characteristics. Our results suggest that an increased care burden poses particular strain to the long‐term mental well‐being of mothers.
format Online
Article
Text
id pubmed-9385598
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-93855982022-08-19 Changes in parents' psychotropic medication use following child's cancer diagnosis: A fixed‐effects register‐study in Finland Metsä‐Simola, Niina S. Remes, Hanna M. Hiltunen, Elina M. Martikainen, Pekka T. Cancer Med RESEARCH ARTICLES BACKGROUND: Symptoms of depression and anxiety are elevated among parents of children with cancer. However, knowledge of parents' psychotropic medication use following child's cancer diagnosis is scarce. METHODS: We use longitudinal Finnish register data on 3266 mothers and 2687 fathers whose child (aged 0–19) was diagnosed with cancer during 2000–2016. We record mothers' and fathers' psychotropic medication use (at least one annual purchase of anxiolytics, hypnotics, sedatives, or antidepressants) 5 years before and after the child's diagnosis and assess within‐individual changes in medication use by time since diagnosis, cancer type, child's age, presence of siblings, and parent's living arrangements and education using linear probability models with the individual fixed‐effects estimator. The fixed‐effects models compare each parent's annual probability of psychotropic medication use after diagnosis to their annual probability of medication use during the 5‐year period before the diagnosis. RESULTS: Psychotropic medication use was more common among mothers than fathers already before the child's diagnosis, 11.2% versus 7.3%. Immediately after diagnosis, psychotropic medication use increased by 6.0 (95% CI 4.8–7.2) percentage points among mothers and by 3.2 (CI 2.1–4.2) percentage points among fathers. Among fathers, medication use returned to pre‐diagnosis level by the second year, except among those whose child was diagnosed with acute lymphoblastic leukemia or lymphoblastic lymphoma. Among mothers of children with a central nervous system cancer, medication use remained persistently elevated during the 5‐year follow‐up. For mothers with other under‐aged children or whose diagnosed child was younger than 10 years, the return to pre‐diagnosis level was also slow. CONCLUSIONS: Having a child with cancer clearly increases parents' psychotropic medication use. The increase is smaller and more short‐lived among fathers, but among mothers its duration depends on both cancer type and family characteristics. Our results suggest that an increased care burden poses particular strain to the long‐term mental well‐being of mothers. John Wiley and Sons Inc. 2022-03-28 /pmc/articles/PMC9385598/ /pubmed/35345057 http://dx.doi.org/10.1002/cam4.4662 Text en © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle RESEARCH ARTICLES
Metsä‐Simola, Niina S.
Remes, Hanna M.
Hiltunen, Elina M.
Martikainen, Pekka T.
Changes in parents' psychotropic medication use following child's cancer diagnosis: A fixed‐effects register‐study in Finland
title Changes in parents' psychotropic medication use following child's cancer diagnosis: A fixed‐effects register‐study in Finland
title_full Changes in parents' psychotropic medication use following child's cancer diagnosis: A fixed‐effects register‐study in Finland
title_fullStr Changes in parents' psychotropic medication use following child's cancer diagnosis: A fixed‐effects register‐study in Finland
title_full_unstemmed Changes in parents' psychotropic medication use following child's cancer diagnosis: A fixed‐effects register‐study in Finland
title_short Changes in parents' psychotropic medication use following child's cancer diagnosis: A fixed‐effects register‐study in Finland
title_sort changes in parents' psychotropic medication use following child's cancer diagnosis: a fixed‐effects register‐study in finland
topic RESEARCH ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9385598/
https://www.ncbi.nlm.nih.gov/pubmed/35345057
http://dx.doi.org/10.1002/cam4.4662
work_keys_str_mv AT metsasimolaniinas changesinparentspsychotropicmedicationusefollowingchildscancerdiagnosisafixedeffectsregisterstudyinfinland
AT remeshannam changesinparentspsychotropicmedicationusefollowingchildscancerdiagnosisafixedeffectsregisterstudyinfinland
AT hiltunenelinam changesinparentspsychotropicmedicationusefollowingchildscancerdiagnosisafixedeffectsregisterstudyinfinland
AT martikainenpekkat changesinparentspsychotropicmedicationusefollowingchildscancerdiagnosisafixedeffectsregisterstudyinfinland